Results from the randomized phase II FAKTION trial showed that the addition of capivasertib to fulvestrant prolongs survival in ER+/HER2- advanced breast cancer and suggest that capivasertib primarily benefits patients with PI3K/AKT/PTEN pathway alterations.
Compared with placebo, pembrolizumab added to neoadjuvant chemotherapy was associated with lower residual cancer burden in patients with TNBC and with prolonged EFS even in patients without a pCR.
Pembrolizumab + chemotherapy ± bevacizumab prolonged PFS and OS vs placebo + chemotherapy ± bevacizumab in key patient populations, including those defined by bevacizumab use, histology, platinum use, and prior chemoradiotherapy.
Tisotumab vedotin plus pembrolizumab demonstrated promising, durable antitumor activity with a tolerable safety profile in recurrent or metastatic cervical cancer.
Dostarlimab was associated with overall response rates of 45.4% and 15.4%, including durable responses, in dMMR/MSI-H and pMMR/MSS advanced/recurrent endometrial cancer.
In the ORZORA trial, maintenance olaparib showed similar OS outcomes in patients with platinum-sensitive relapsed ovarian cancer regardless of whether patients had a germline or a somatic BRCA mutation or a non-BRCA HRR mutation.
Addition of the GR modulator relacorilant to nab-paclitaxel numerically improved OS vs nab-paclitaxel alone in patients with recurrent platinum-resistant ovarian cancer.
First interim analysis finds that sacituzumab govitecan extends progression-free survival in patients with heavily pretreated metastatic HR-positive/HER2-negative breast cancer.
Final results showed no significant difference in overall survival with the addition of palbociclib to frontline letrozole in postmenopausal patients with ER-positive/HER2-negative breast cancer.
Ribociclib combined with switching endocrine therapy improved PFS in patients with HR-positive/HER2-negative metastatic breast cancer who progressed on prior standard of care CDK4/6 inhibition with endocrine therapy.
Trastuzumab deruxtecan improves survival in patients with HER2 IHC1+ and IHC2+/ISH-negative advanced breast cancer.
Women with clinically favorable low-risk breast cancer demonstrated a 5-year rate of local recurrence of less than 5% after breast-conserving survey and endocrine therapy without radiotherapy.
First-line maintenance therapy with rucaparib significantly improved PFS vs placebo regardless of HRD status in patients with advanced ovarian cancer.
In MITO23, trabectedin failed to improve survival compared with investigator’s choice of single-agent chemotherapy in patients with BRCA-mutant or BRCAness phenotype recurrent ovarian cancer.